ClinicalTrials.gg
Active, not recruitingNCT04927780PREOPANC-3Updated May 15, 2026

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

A Phase 3 interventional study of Leucovorin Calcium and Fluorouracil in Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma and Resectable Pancreatic Adenocarcinoma, sponsored by Erasmus Medical Center. Active, not recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Erasmus Medical Center · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies testing leucovorin in Pancreatic Neoplasms — 8 open to participants now, 12 under way, 4 of them phase 3. Leucovorin · Pancreatic Neoplasms.

Planned enrollment
4th of 37
378 · median 80
Started
2021
with 3 others
Phase 3
8 of 37
2 open now
Primary completion
2027-01
later than 6 of 11 live
Registered
30th of 37
by date

Among the 37 studies testing leucovorin in Pancreatic Neoplasms, this one is the 4th largest by planned enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, reaches primary completion later than 6 of the 11 other live ones, and was the 30th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

8 of the 37 studies testing leucovorin in Pancreatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About leucovorin

Leucovorin: first FDA approval 1952 (LEUCOVORIN CALCIUM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing leucovorin in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2).

The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.

03

Conditions studied

  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Resectable Pancreatic Adenocarcinoma

Keywords

  • Neoadjuvant Therapy
  • Adjuvant Chemotherapy
  • Oxaliplatin
  • Irinotecan
  • Leucovorin
  • Fluorouracil
  • Pancreatic Neoplasms
  • Pancreatectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically or cytologically (Bethesda 5 or 6) confirmed pancreatic ductal adenocarcinoma.
  • Resectable tumor according to Dutch Pancreatic Cancer Group criteria: no arterial contact and venous contact with the superior mesenteric vein or portal vein of 90 degrees or less
  • No evidence for disease
  • of 0 or 1
  • Ability to undergo surgery and mFOLFIRINOX chemotherapy
  • Leucocytes (WBC) ≥ 3.0 x 10\^9/L
  • ≥ 100 x 10\^9/L
  • ≥ 6.0 mmol/l
  • Renal function: ≥ 40 ml/min
  • Age ≥ 18 years
  • Written

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy, chemotherapy, or surgery for pancreatic cancer.
  • Prior chemotherapy precluding mFOLFIRINOX.
  • Previous (excluding non-melanoma skin cancer, pancreatic neuroendocrine tumor (pNET) \<2cm, and gastrointestinal stromal tumor (GIST) \<2cm), unless no evidence of disease and diagnosed more than 3 years before diagnosis of pancreatic cancer, or with a of more than 5 years from date of inclusion.
  • Pregnancy or lactation.
  • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
378 participants (estimated)

Study arms

  • Experimental
    Arm 1: Perioperative mFOLFIRINOX

    Patients in the intervention arm (arm 1) start with neoadjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours). Cycles are repeated every 14 days. After eight cycles, surgical resection is performed in the absence of unresectable or metastatic disease. After resection, four cycles of adjuvant mFOLFIRINOX are scheduled.

    Drug: Leucovorin Calcium · Drug: Fluorouracil · Drug: Irinotecan Hydrochloride · Drug: Oxaliplatin · Procedure: Resection

  • Active comparator
    Arm 2: Adjuvant mFOLFIRINOX

    Patients in the comparator arm (arm 2) start with surgery. After resection, 12 cycles of adjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours) are scheduled.

    Drug: Leucovorin Calcium · Drug: Fluorouracil · Drug: Irinotecan Hydrochloride · Drug: Oxaliplatin · Procedure: Resection

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival

    The time between randomization and death from any cause. Patients alive at last follow-up are censored.

    Time frame: Up to 5 years after randomization.

Secondary outcomes

  1. Progression free survival

    The time between randomization and locoregional progressive disease before or during treatment (resulting in irresectability), the occurrence of distant metastases, recurrent pancreatic cancer after surgery or death from any cause. Patients alive and free of these events at last follow-up are censored.

    Time frame: Up to 5 years after randomization.

  2. Distant metastases free survival

    The time between randomization and the occurrence of distant metastases or death from any cause. Patients alive and free of these events at last follow-up are censored.

    Time frame: Up to 5 years after randomization.

  3. Locoregional progression free survival

    The time between randomization and locoregional progression before or during treatment (resulting in irresectability), locoregional recurrence after resection or death from any cause. Patients alive and free of these events at last follow-up are censored.

    Time frame: Up to 5 years after randomization.

  4. Distant metastases free interval

    The time between randomization and the occurrence of distant metastases. Distant metastases are considered an event and patients are censored at death or last follow-up when without this event.

    Time frame: Up to 5 years after randomization.

  5. Locoregional progression free interval

    The time between randomization and locoregional progression before or during treatment (resulting in irresectability), or locoregional recurrence after resection. Locoregional progressive disease before or during treatment or locoregional recurrence after resection are considered an event and patients are censored at death or last follow-up when free of these events.

    Time frame: Up to 5 years after randomization.

  6. Chemotherapy start rate

    The percentage of patients who received at least one cycle of scheduled chemotherapy.

    Time frame: 4 months

  7. Number of chemotherapy cycles received.

    The number of mFOLFIRINOX cycles patients received.

    Time frame: 9 months

  8. Chemotherapy completion rate

    The percentage of patients who completed all cycles of scheduled chemotherapy.

    Time frame: 9 months

  9. Dose intensity

    The amount of drug delivered as a percentage of planned dose according to the protocol.

    Time frame: 9 months

  10. Staging laparoscopy rate

    The percentage of patients that actually underwent a staging laparoscopy, regardless whether a surgical exploration or resection was performed.

    Time frame: At the time of surgery.

  11. Laparoscopy yield

    The percentage of patients that underwent staging laparoscopy and were diagnosed with metastatic or unresectable disease during this procedure.

    Time frame: At the time of surgery.

  12. Surgical exploration rate

    The percentage of patients who underwent a surgical exploration (open or minimally-invasive), regardless whether a resection was performed.

    Time frame: At the time of surgery.

  13. Resection rate

    The percentage of patients that underwent a curative-intent resection.

    Time frame: At the time of surgery.

  14. Microscopically margin-negative (R0) resection rate

    The percentage of patients that underwent a microscopically margin-negative (R0) resection. The resection is considered R0 if there is no tumor within 1 mm of the margins.

    Time frame: At the time of surgery.

  15. Lymph node-negative (N0) resection rate

    The percentage of patients that underwent a resection with negative lymph nodes (N0) in the surgical specimen.

    Time frame: At the time of surgery.

  16. Pathologic response

    Tumor regression score in the surgical specimen

    Time frame: At the time of surgery.

  17. Adverse events as assessed by the CTCAE version 5.0

    Adverse events are assessed during neoadjuvant therapy and adjuvant therapy.

    Time frame: Until 30 days after last chemotherapy.

  18. Postoperative complications

    According to the Clavien-Dindo classification and by the International Study Group of Pancreatic Surgery and International Study Group of Liver Surgery.

    Time frame: Up to 90 days after surgery.

  19. Serum CA 19-9 and CEA response

    The change in carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) after surgery and after 4, 8, and 12 cycles of mFOLFIRINOX compared to baseline.

    Time frame: 9 months

  20. Clinical response rate according to RECIST criteria version 1.1

    Response comparing baseline and restaging after 4 and 8 cycles of mFOLFIRINOX

    Time frame: At the time of surgery.

  21. Patient reported cancer-specific health-related Quality of Life (HRQoL) as assessed using the EORTC QLQ-C30

    At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year

    Time frame: Up to 5 years after randomization.

  22. Patient reported non-disease specific HRQoL as assessed using the EQ-5D-5L

    At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year

    Time frame: Up to 5 years after randomization.

  23. Patient reported tumor-specific HRQoL as assessed using the EORTC LQPAN26

    At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year

    Time frame: Up to 5 years after randomization.

  24. Patient reported Quality of Life as assessed using the worry of progression of cancer scale (WOPS)

    At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year

    Time frame: Up to 5 years after randomization.

  25. Patient reported chemotherapy-induced peripheral neuropathy as assessed using the EORTC QLQ-CIPN20

    At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year

    Time frame: Up to 5 years after randomization.

  26. Patient reported Quality of Life as assessed using the happiness, hospital, anxiety and depression scale (HADS)

    At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year

    Time frame: Up to 5 years after randomization.

  27. Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire

    At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year

    Time frame: Up to 5 years after randomization.

07

Study locations

21 sites
08

References and documents

Publications

  • van Dam JL, Verkolf EMM, Dekker EN, Bonsing BA, Bratlie SO, Brosens LAA, Busch OR, van Driel LMJW, van Eijck CHJ, Feshtali S, Ghorbani P, de Groot DJA, de Groot JWB, Haberkorn BCM, de Hingh IH, van der Holt B, Karsten TM, van der Kolk MB, Labori KJ, Liem MSL, Loosveld OJL, Molenaar IQ, Polee MB, van Santvoort HC, de Vos-Geelen J, Wumkes ML, van Tienhoven G, Homs MYV, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer. 2023 Aug 7;23(1):728. doi: 10.1186/s12885-023-11141-5. PubMed 37550634 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Jan 2027, 64 months after the start.

Of 46 non-industry phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 79. This study's planned 64 months is close to that.

Counting every sponsor, half of 84 studies reached it within 60 months; a quarter within 36 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Jun 16, 2021
StartActual
Sep 7, 2021
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2029
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04927780
Collaborators
Dutch Pancreatic Cancer Group, Dutch Cancer Society
Responsible party
Bas Groot Koerkamp, MD, PhD (Principal Investigator, Erasmus Medical Center) — Principal investigator
First posted
Jun 16, 2021
Start date
Sep 7, 2021
Primary completion
Jan 2027 (estimated)
Completion
Jul 2029 (estimated)
Last update
May 15, 2026

Study contacts

Bas Groot Koerkamp, MD, PhD
principal investigator · Erasmus MC University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Leucovorin · Fluorouracil · Irinotecan · Oxaliplatin

Start the discussion